** Shares of Invion rise as much as 130.6% to A$0.415, posting their biggest intraday percentage gain since Oct. 28, 2021
** Stock hits its highest level since July 16
** Cancer treatment developer says the first patient has been dosed in the early-stage trial of its light absorbing material "INV043", aimed to treat non-melanoma skin cancer
** About 483,000 shares change hands, compared with the 30-day average volume of around 37,000
** Stock trims YTD losses to 30%, including session's move
(Reporting by Aaditya Govind Rao in Bengaluru)
((Aaditya.govindrao@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。